CTD regimen: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} {{CMG}}; {{AE}} {{AV}} | {{SI}} {{CMG}}; {{AE}} {{AV}} | ||
==Overview== | ==Overview== |
Latest revision as of 18:26, 12 March 2015
WikiDoc Resources for CTD regimen |
Articles |
---|
Most recent articles on CTD regimen Most cited articles on CTD regimen |
Media |
Powerpoint slides on CTD regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on CTD regimen at Clinical Trials.gov Clinical Trials on CTD regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on CTD regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on CTD regimen Discussion groups on CTD regimen Patient Handouts on CTD regimen Directions to Hospitals Treating CTD regimen Risk calculators and risk factors for CTD regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for CTD regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
CTD regimen refers to a regimen consisting of Cyclophosphamide, Thalidomide, Dexamethasone used to treat Multiple myeloma unsuitable for autologous transplantation[1]
Regimen
CCyclophosphamide
TThalidomide
DDexamethasone
Indications
References
- ↑ 1.0 1.1 Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ; et al. (2011). "Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation". Blood. 118 (5): 1231–8. doi:10.1182/blood-2011-02-338665. PMC 3152492. PMID 21652683.